 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com cut shares of Aclaris Therapeutics (NASDAQ:ACRS - Free Report) from a hold rating to a sell rating in a research note released on Tuesday morning.
Several other brokerages also recently...

Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to Sell at StockNews.com

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling...

Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Declines By 16.1%

StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS  Free Report) from a sell rating to a hold rating in a research report released on Monday morning.
Other equities research...

Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to Hold at StockNews.com

Biotech's Role in Addressing the Pancreatic Cancer Emergency Biotech's Role in Addressing the Pancreatic Cancer Emergency PR Newswire VANCOUVER, BC, March 14, 2024 FN Media Group Presents USA News...

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Investors considering a purchase of Aclaris Therapeutics Inc (ACRS) stock, but tentative about paying the going market price of 1.29/share, might benefit from considering selling puts among the...

Commit To Purchase Aclaris Therapeutics At $0.50, Earn 23.4% Annualized Using Options

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Connect Biopharma Holdings (CNTB Research Report), Aethlon Medical...

Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)

H.C. Wainwright analyst Ram Selvaraju has reiterated their neutral stance on ACRS stock, giving a Hold rating on February 27. Ram Selvaraju has giv...

Aclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline Potential

Algert Global LLC purchased a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS  Free Report) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 45,120 shares of the...

Algert Global LLC Buys New Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics, Inc. (NASDAQ:ACRS  Get Free Report) has been given an average recommendation of Hold by the eight research firms that are currently covering the company...

Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $23.17

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Volume (M)	579,779.00
52-Wk High	$11.12
52-Wk Low	$0.5902

ACRS Aclaris Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals